Pulmonary: Frequently Asked Questions

Pulmonary medicine encompasses the diagnosis, treatment, and management of disorders affecting the lungs, airways, and broader respiratory system. These questions address the most common points of confusion — from how authoritative clinical guidance is produced to what triggers a specialist referral and how lung conditions are formally classified. The answers below draw on named regulatory agencies, professional societies, and published clinical frameworks to give grounded, reference-quality responses.

Where can authoritative references be found?

The primary sources for pulmonary medicine guidance are the American Thoracic Society (ATS), the European Respiratory Society (ERS), the American College of Chest Physicians (ACCP), and the National Heart, Lung, and Blood Institute (NHLBI). Each publishes clinical practice guidelines, position statements, and consensus documents that are indexed in PubMed and available on their respective official websites.

For regulatory and public health framing, the Centers for Disease Control and Prevention (CDC) maintains surveillance data on respiratory diseases including tuberculosis and occupational exposures. The Occupational Safety and Health Administration (OSHA) publishes permissible exposure limits relevant to occupational lung disease at osha.gov. The National Institutes of Health (NIH) MedlinePlus database provides patient-accessible summaries linked directly to clinical trial registries and guideline documents.

For an orientation to the field as a whole, the Pulmonary Authority index organizes topics by condition, diagnostic test, treatment, and clinical sign.

How do requirements vary by jurisdiction or context?

Pulmonary care standards shift across three primary dimensions: clinical setting, payer framework, and geographic jurisdiction.

At the federal level, the Centers for Medicare & Medicaid Services (CMS) defines coverage criteria for services such as oxygen therapy, CPAP and BiPAP for sleep apnea, and pulmonary rehabilitation — each with distinct diagnostic threshold requirements. For example, CMS requires documented arterial oxygen partial pressure at or below 55 mmHg, or oxygen saturation at or below 88 percent, to qualify for home oxygen under the LCD framework (CMS Local Coverage Determinations).

State medical boards govern physician licensure, and scope-of-practice rules for respiratory therapists (credentialed through the National Board for Respiratory Care, NBRC) vary by state. Internationally, ERS guidelines may diverge from ATS recommendations on spirometry interpretation cutoffs or COPD staging thresholds.

What triggers a formal review or action?

Formal clinical review in pulmonary medicine is typically initiated by 4 categories of findings:

  1. Abnormal imaging — a nodule, mass, or infiltrate on chest X-ray or CT scan that does not resolve within a defined surveillance window
  2. Abnormal pulmonary function — pulmonary function test results showing obstruction, restriction, or diffusion impairment beyond established normal ranges (typically defined as below the lower limit of normal, or LLN, per ATS/ERS 2022 interpretation standards)
  3. Hypoxemia at rest or exertion — pulse oximetry or arterial blood gas values outside accepted thresholds
  4. Unresolved or worsening symptoms — persistent chronic cough, shortness of breath, or wheezing lasting beyond 8 weeks without an identified cause

Lung cancer screening triggers formal action when a Lung-RADS category 3 or higher result is returned on low-dose CT, per ACR Lung-RADS v2022 criteria.

How do qualified professionals approach this?

Pulmonologists complete internal medicine residency (3 years) followed by a fellowship of at least 2 years in pulmonary medicine, and frequently an additional year for critical care. Board certification is administered through the American Board of Internal Medicine (ABIM), which requires passage of a subspecialty examination. Details on the credentialing pathway are covered under pulmonary board certification.

In practice, a qualified pulmonologist applies a structured diagnostic framework: history and physical examination, objective testing (spirometry, imaging, oximetry), differential diagnosis construction, and — when indicated — procedural evaluation via bronchoscopy or thoracentesis. Interventional pulmonology is a further subspecialty focused on advanced bronchoscopic and pleural procedures.

Respiratory therapists (RTs) work within physician-directed care plans and hold licensure requirements governed individually by state statutes.

What should someone know before engaging?

Before a first pulmonology visit, 5 categories of preparation improve diagnostic efficiency:

  1. Compile a list of all respiratory symptoms, including onset date, duration, and aggravating or relieving factors
  2. Bring all prior imaging reports and, where possible, the actual image files (DICOM format or CD)
  3. Document current medications, including all inhaler devices with dosing frequency
  4. Identify occupational and environmental exposures — relevant to occupational lung disease and air quality effects on lung health
  5. Bring records of prior spirometry or sleep studies if available

Patients referred for lung cancer screening should understand that low-dose CT is a screening tool, not a diagnostic test — a positive screen triggers a structured follow-up protocol, not an immediate diagnosis. Signs that indicate a pulmonologist referral is warranted include recurrent pneumonia, unexplained hypoxemia, or spirometry showing greater than 10 percent decline in FEV₁ over 12 months.

What does this actually cover?

Pulmonary medicine covers disorders of the lower respiratory tract, the pleural space, and — in practice — the intersection of sleep physiology with breathing. Major condition categories include:

The field interfaces directly with thoracic surgery for surgical management and with pediatric pulmonology for patients under 18. A structured overview of the full scope appears at what is pulmonology.

What are the most common issues encountered?

Across pulmonary practice, 6 issues generate the largest volume of diagnostic and management activity:

  1. Delayed COPD diagnosis — spirometric confirmation is required per GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria, yet GOLD estimates that diagnosis is missed in a substantial proportion of patients with post-bronchodilator FEV₁/FVC below 0.70
  2. Inhaler technique errors — studies published in the journal Chest have found incorrect technique in more than 70 percent of patients using metered-dose or dry powder inhalers, directly reducing drug delivery
  3. Undiagnosed obstructive sleep apnea — the American Academy of Sleep Medicine estimates prevalence of moderate-to-severe OSA at approximately 10 percent in adults aged 30–70
  4. Distinguishing cardiac from pulmonary dyspnea — covered in detail at shortness of breath: pulmonary vs. cardiac
  5. Pulmonary nodule management — adherence to Fleischner Society guidelines for nodule follow-up remains inconsistent across practice settings
  6. Underutilization of pulmonary rehabilitation — despite Class I evidence supporting pulmonary rehabilitation in COPD, referral rates remain low in primary care settings (ATS/ERS position statement on pulmonary rehabilitation)

How does classification work in practice?

Pulmonary conditions are classified along two primary axes: physiologic pattern and etiologic category.

The physiologic axis relies on spirometry and lung volume measurement. ATS/ERS 2022 interpretation guidelines define three patterns:

The etiologic axis further classifies conditions by cause — infectious, inflammatory, vascular, neoplastic, environmental, or genetic. Pulmonary fibrosis, for instance, sits in the restrictive-inflammatory category, while pulmonary embolism is classified as vascular-obstructive in a different sense (impaired vascular flow rather than airway obstruction).

For neoplastic classification, lung cancer staging follows the TNM system maintained by the American Joint Committee on Cancer (AJCC), 8th edition, which defines Stage I through Stage IV based on tumor size, nodal involvement, and metastasis. Lung cancer screening programs exist precisely to identify disease at Stage I, when 5-year survival rates are substantially higher than at Stage III or IV.

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)